Significantly, melatonin has been found to inhibit the activation of the NLRP3 inflammasome, suggesting that melatonin treatment during COVID-19 or periodontal diseases could alleviate the damage observed in periodontal tissues [59]. The gene discussed is NLRP3; the disease is COVID-19.